UroGen Pharma Announces Proposed Public Offering of Ordinary Shares
Last urogen pharma ltd earnings: 3/2 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations: investors.urogen.com
NEW YORK--(BUSINESS WIRE)-- UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a focus on uro-oncology, today announced that it intends to offer and sell $150 million of its ordinary shares in an underwritten public offering. The company also intends to grant the underwriters a 30-day option to purchase up to an additional 15 percent of the number of ordinary shares sold in the offering at the public offering price, less the underwriting discounts and commissions. The offering is subject to market and other conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. All ordinary shares to be sold in this offering will be offered by the company. Goldman Sachs & Co. LLC, J.P. Morgan and Jefferies are acting as joint book-ru
[Read more]
| Impact snapshot | Event time: | URGN | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last price | ||
| VWAP | ||
|
High:
|
Max up |
High:
|
|
Low:
|
Max down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event Day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance Since Event
Time and Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
SIGN UP TODAY
Opt-in for
URGN alerts
URGN alerts
from News Quantified
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
URGN alerts
High impacting UroGen Pharma Ltd news events
Weekly update
A roundup of the hottest topics
URGN
News
- UroGen Pharma Ltd. (<a href="https://www.marketbeat.com/stocks/NASDAQ/URGN/price-target/">NASDAQ: URGN</a>) had its "buy" rating re-affirmed by analysts at HC Wainwright.MarketBeat
- UroGen Pharma teams up with MD Anderson to advance treatment for bladder cancer [Seeking Alpha]Seeking Alpha
- UroGen Pharma and MD Anderson Announce Strategic Research Collaboration to Advance Investigational Treatment for High-Grade Bladder CancerBusiness Wire
- UroGen Pharma to Present at the Virtual 39th Annual J.P. Morgan Healthcare ConferenceBusiness Wire
- UroGen Pharma Ltd. (<a href="https://www.marketbeat.com/stocks/NASDAQ/URGN/price-target/">NASDAQ: URGN</a>) was downgraded by analysts at BidaskClub from a "sell" rating to a "strong sell" rating.MarketBeat
- More
URGN
SEC Filings
- 1/13/21 - Form 8-K
- 1/11/21 - Form 8-K
- 12/15/20 - Form 4
- URGN's page on the SEC website
- More